[FG] Yaldizli Özgür
Publications
172 found
Show per page
Rom, A. et al. (2026) ‘Spinal ischemia after prolonged resuscitation and coronary angiography under Impella protection’, European Journal of Case Reports in Internal Medicine [Preprint]. Available at: https://doi.org/10.12890/2026_006023.
Rom, A. et al. (2026) ‘Spinal ischemia after prolonged resuscitation and coronary angiography under Impella protection’, European Journal of Case Reports in Internal Medicine [Preprint]. Available at: https://doi.org/10.12890/2026_006023.
Maceski, Aleksandra Maleska et al. (2025) ‘GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis’, Brain [Preprint]. Available at: https://doi.org/10.1093/brain/awaf433.
Maceski, Aleksandra Maleska et al. (2025) ‘GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis’, Brain [Preprint]. Available at: https://doi.org/10.1093/brain/awaf433.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12, pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Einsiedler, Maximilian et al. (2025) ‘Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response’, Annals of Clinical and Translational Neurology, 12, pp. 2214–2225. Available at: https://doi.org/10.1002/acn3.70149.
Cagol, Alessandro et al. (2025) ‘Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13221-x.
Cagol, Alessandro et al. (2025) ‘Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13221-x.
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum Real-World Data From the Swiss Multiple Sclerosis Cohort’, Neurology Clinical Practice, 15. Available at: https://doi.org/10.1212/CPJ.0000000000200499.
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum Real-World Data From the Swiss Multiple Sclerosis Cohort’, Neurology Clinical Practice, 15. Available at: https://doi.org/10.1212/CPJ.0000000000200499.
Yaldizli, Özgür et al. (2025) ‘Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study’, Multiple Sclerosis Journal, 31, pp. 932–943. Available at: https://doi.org/10.1177/13524585251335466.
Yaldizli, Özgür et al. (2025) ‘Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study’, Multiple Sclerosis Journal, 31, pp. 932–943. Available at: https://doi.org/10.1177/13524585251335466.
Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology. 14.04.2025, 82(6), pp. 614–625. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.
Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology. 14.04.2025, 82(6), pp. 614–625. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.
Iaquinto, Stefania et al. (2025) ‘Confirmed Worsening of Health-Related Quality of Life to Monitor Long-Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70230.
Iaquinto, Stefania et al. (2025) ‘Confirmed Worsening of Health-Related Quality of Life to Monitor Long-Term MS Disease Progression: A Longitudinal Analysis From the Swiss Multiple Sclerosis Registry’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70230.
Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.
Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.
Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology. 16.10.2024, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.
Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology. 16.10.2024, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.
Disanto, Giulio et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 11. Available at: https://doi.org/10.1177/20552173251315457.
Disanto, Giulio et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 11. Available at: https://doi.org/10.1177/20552173251315457.
Durrer, Alicia (2025) Leveraging Denoising Diffusion Probabilistic Models for Brain Magnetic Resonance Image Processing and Analysis. Doctoral Thesis. University of Basel.
Durrer, Alicia (2025) Leveraging Denoising Diffusion Probabilistic Models for Brain Magnetic Resonance Image Processing and Analysis. Doctoral Thesis. University of Basel.
Durrer, Alicia et al. (2025) ‘Denoising Diffusion Models for 3D Healthy Brain Tissue Inpainting’, in Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) . Marrakesh, Morocco: Springer Science and Business Media Deutschland GmbH (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) ), pp. 87–97. Available at: https://doi.org/10.1007/978-3-031-72744-3_9.
Durrer, Alicia et al. (2025) ‘Denoising Diffusion Models for 3D Healthy Brain Tissue Inpainting’, in Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) . Marrakesh, Morocco: Springer Science and Business Media Deutschland GmbH (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) ), pp. 87–97. Available at: https://doi.org/10.1007/978-3-031-72744-3_9.
Hench, J. et al. (2024) ‘Rapid brain lymphoma diagnostics through nanopore sequencing of cytology-negative cerebrospinal fluid’, Acta Neuropathologica, 148(1). Available at: https://doi.org/10.1007/s00401-024-02793-z.
Hench, J. et al. (2024) ‘Rapid brain lymphoma diagnostics through nanopore sequencing of cytology-negative cerebrospinal fluid’, Acta Neuropathologica, 148(1). Available at: https://doi.org/10.1007/s00401-024-02793-z.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25. Available at: https://doi.org/10.1186/s13063-024-08454-6.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25. Available at: https://doi.org/10.1186/s13063-024-08454-6.
Cortese, Rosa et al. (2024) ‘Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis’, Annals of Neurology, 96(2), pp. 276–288. Available at: https://doi.org/10.1002/ana.26951.
Cortese, Rosa et al. (2024) ‘Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis’, Annals of Neurology, 96(2), pp. 276–288. Available at: https://doi.org/10.1002/ana.26951.
Müller, Jannis et al. (2024) ‘Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis’, Brain and Behavior. 30.04.2024, 14(5). Available at: https://doi.org/10.1002/brb3.3498.
Müller, Jannis et al. (2024) ‘Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis’, Brain and Behavior. 30.04.2024, 14(5). Available at: https://doi.org/10.1002/brb3.3498.
Hirt, Julian et al. (2024) ‘Use of pragmatic randomized trials in multiple sclerosis: A systematic overview’, Multiple Sclerosis Journal, 30(4-5), pp. 463–478. Available at: https://doi.org/10.1177/13524585231221938.
Hirt, Julian et al. (2024) ‘Use of pragmatic randomized trials in multiple sclerosis: A systematic overview’, Multiple Sclerosis Journal, 30(4-5), pp. 463–478. Available at: https://doi.org/10.1177/13524585231221938.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv (Cold Spring Harbor Laboratory) [Preprint]. Cold Spring Harbor Laboratory (medRxiv (Cold Spring Harbor Laboratory)). Available at: https://doi.org/10.1101/2024.03.22.24304720.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv (Cold Spring Harbor Laboratory) [Preprint]. Cold Spring Harbor Laboratory (medRxiv (Cold Spring Harbor Laboratory)). Available at: https://doi.org/10.1101/2024.03.22.24304720.
Rusche, Thilo et al. (2024) ‘Anti-GABAA receptor encephalitis 14 months after allogeneic haematopoietic stem-cell transplant for acute myeloid leukaemia’, The Lancet, 403(10425), pp. 469–470. Available at: https://doi.org/10.1016/s0140-6736(23)02831-3.
Rusche, Thilo et al. (2024) ‘Anti-GABAA receptor encephalitis 14 months after allogeneic haematopoietic stem-cell transplant for acute myeloid leukaemia’, The Lancet, 403(10425), pp. 469–470. Available at: https://doi.org/10.1016/s0140-6736(23)02831-3.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.
Iaquinto, Stefania et al. (2024) ‘Rising Prevalence of Multiple Sclerosis in Switzerland: Results from the Swiss Multiple Sclerosis Registry’, Neuroepidemiology [Preprint]. Available at: https://doi.org/10.1159/000542632.
Iaquinto, Stefania et al. (2024) ‘Rising Prevalence of Multiple Sclerosis in Switzerland: Results from the Swiss Multiple Sclerosis Registry’, Neuroepidemiology [Preprint]. Available at: https://doi.org/10.1159/000542632.
Mueller, Simon M. et al. (2024) ‘Serum Neurofilament Light Chain Levels Correlate With Skin Inflammation and Scratch Lesions in Patients With Pruritus’, Dermatologic Therapy, 2024. Available at: https://doi.org/10.1155/2024/3542876.
Mueller, Simon M. et al. (2024) ‘Serum Neurofilament Light Chain Levels Correlate With Skin Inflammation and Scratch Lesions in Patients With Pruritus’, Dermatologic Therapy, 2024. Available at: https://doi.org/10.1155/2024/3542876.
Müller, Jannis et al. (2023) ‘Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis’, European Journal of Neurology, 30(12), pp. 3809–3818. Available at: https://doi.org/10.1111/ene.16044.
Müller, Jannis et al. (2023) ‘Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis’, European Journal of Neurology, 30(12), pp. 3809–3818. Available at: https://doi.org/10.1111/ene.16044.
Stanikić, Mina et al. (2023) ‘Self-reports by persons with multiple sclerosis are an adequate surrogate for healthcare provider data on disease-modifying therapy and multiple sclerosis type’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105097.
Stanikić, Mina et al. (2023) ‘Self-reports by persons with multiple sclerosis are an adequate surrogate for healthcare provider data on disease-modifying therapy and multiple sclerosis type’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105097.
Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review’, JAMA Neurology. 02.10.2023, 80(11), pp. 1232–1245. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.
Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review’, JAMA Neurology. 02.10.2023, 80(11), pp. 1232–1245. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.
Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.
Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.
Meier, S. et al. (2023) ‘Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016)’, Neurology, 100(17_supplement_2). Available at: https://doi.org/10.1212/wnl.0000000000203030.
Meier, S. et al. (2023) ‘Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016)’, Neurology, 100(17_supplement_2). Available at: https://doi.org/10.1212/wnl.0000000000203030.
Meier, Stephanie et al. (2023) ‘Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis’, JAMA Neurology, 80(3), pp. 287–297. Available at: https://doi.org/10.1001/jamaneurol.2022.5250.
Meier, Stephanie et al. (2023) ‘Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis’, JAMA Neurology, 80(3), pp. 287–297. Available at: https://doi.org/10.1001/jamaneurol.2022.5250.
Cerdá-Fuertes, Nuria et al. (2023) ‘Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150312.
Cerdá-Fuertes, Nuria et al. (2023) ‘Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150312.
Durrer, Alicia et al. (2023) ‘Diffusion Models for Contrast Harmonization of Magnetic Resonance Images’, in Proceedings of Machine Learning Research. (Proceedings of Machine Learning Research), pp. 526–551.
Durrer, Alicia et al. (2023) ‘Diffusion Models for Contrast Harmonization of Magnetic Resonance Images’, in Proceedings of Machine Learning Research. (Proceedings of Machine Learning Research), pp. 526–551.
Etter, Manina M. et al. (2022) ‘Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study’, Nature Communications, 13. Available at: https://doi.org/10.1038/s41467-022-34068-0.
Etter, Manina M. et al. (2022) ‘Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study’, Nature Communications, 13. Available at: https://doi.org/10.1038/s41467-022-34068-0.
Etter M et al. (2022) ‘Severe Neuro-COVID is associated with peripheral immune signatures and signs of neurodegeneration: a prospective cross-sectional study’, in SFCNS. (SFCNS).
Etter M et al. (2022) ‘Severe Neuro-COVID is associated with peripheral immune signatures and signs of neurodegeneration: a prospective cross-sectional study’, in SFCNS. (SFCNS).
Yaldizli Ö and Derfuss T (2022) ‘All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Commentary’, Multiple Sclerosis Journal. SAGE Publications Ltd, 28(10). Available at: https://doi.org/10.1177/13524585221097562.
Yaldizli Ö and Derfuss T (2022) ‘All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Commentary’, Multiple Sclerosis Journal. SAGE Publications Ltd, 28(10). Available at: https://doi.org/10.1177/13524585221097562.
Lisa Dinsenbacher and Özgür Yaldizli (2022) ‘MS und Kinderwunsch: Was müssen Betroffene beachten?’, FORTE [Preprint], (3).
Lisa Dinsenbacher and Özgür Yaldizli (2022) ‘MS und Kinderwunsch: Was müssen Betroffene beachten?’, FORTE [Preprint], (3).
Cagol, Alessandro et al. (2022) ‘Association of Brain Atrophy with Disease Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis’, JAMA Neurology, 79, pp. 682–692. Available at: https://doi.org/10.1001/jamaneurol.2022.1025.
Cagol, Alessandro et al. (2022) ‘Association of Brain Atrophy with Disease Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis’, JAMA Neurology, 79, pp. 682–692. Available at: https://doi.org/10.1001/jamaneurol.2022.1025.
Müller, Jannis et al. (2022) ‘Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis’, Neurology: Neuroimmunology and NeuroInflammation, 9(3). Available at: https://doi.org/10.1212/nxi.0000000000001147.
Müller, Jannis et al. (2022) ‘Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis’, Neurology: Neuroimmunology and NeuroInflammation, 9(3). Available at: https://doi.org/10.1212/nxi.0000000000001147.
Kulsvehagen, Laila et al. (2022) ‘Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study’. Research Square Platform LLC. Available at: https://doi.org/10.21203/rs.3.rs-1385593/v1.
Kulsvehagen, Laila et al. (2022) ‘Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study’. Research Square Platform LLC. Available at: https://doi.org/10.21203/rs.3.rs-1385593/v1.
Benkert, Pascal et al. (2022) ‘Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study’, The Lancet Neurology. 16.02.2022, 21(3), pp. 246–257. Available at: https://doi.org/10.1016/s1474-4422(22)00009-6.
Benkert, Pascal et al. (2022) ‘Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study’, The Lancet Neurology. 16.02.2022, 21(3), pp. 246–257. Available at: https://doi.org/10.1016/s1474-4422(22)00009-6.
Müller, J. et al. (2022) ‘On the association between the choroid plexus volume and disease characteristics in multiple sclerosis’, Multiple Sclerosis Journal. Amsterdam: SAGE Publications (38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)), 1 January.
Müller, J. et al. (2022) ‘On the association between the choroid plexus volume and disease characteristics in multiple sclerosis’, Multiple Sclerosis Journal. Amsterdam: SAGE Publications (38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)), 1 January.
Sinnecker, Tim et al. (2022) ‘Brain atrophy measurement over a MRI scanner change in multiple sclerosis’, NeuroImage: Clinical, 36. Available at: https://doi.org/10.1016/j.nicl.2022.103148.
Sinnecker, Tim et al. (2022) ‘Brain atrophy measurement over a MRI scanner change in multiple sclerosis’, NeuroImage: Clinical, 36. Available at: https://doi.org/10.1016/j.nicl.2022.103148.
Wolleb, Julia et al. (2022) ‘Learn to Ignore: Domain Adaptation for Multi-site MRI Analysis’, in Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). Singapore, September 18–22, 2022: Springer Science and Business Media Deutschland GmbH (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)), pp. 725–735. Available at: https://doi.org/10.1007/978-3-031-16449-1_69.
Wolleb, Julia et al. (2022) ‘Learn to Ignore: Domain Adaptation for Multi-site MRI Analysis’, in Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). Singapore, September 18–22, 2022: Springer Science and Business Media Deutschland GmbH (Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)), pp. 725–735. Available at: https://doi.org/10.1007/978-3-031-16449-1_69.
Sophia Reimann et al. (2022) ‘On the association between the choroid plexus volume and disease characteristics in multiple sclerosis’, in SFCNS. (SFCNS).
Sophia Reimann et al. (2022) ‘On the association between the choroid plexus volume and disease characteristics in multiple sclerosis’, in SFCNS. (SFCNS).
Cagol, A. et al. (2021) ‘Progression independent of relapse activity is associated with increased brain atrophy rates in patients with relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal. 12.10.2021, 27(2), pp. 98–99.
Cagol, A. et al. (2021) ‘Progression independent of relapse activity is associated with increased brain atrophy rates in patients with relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal. 12.10.2021, 27(2), pp. 98–99.
Oechtering, Johanna et al. (2021) ‘Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis’, Annals of Neurology, 90, pp. 477–489. Available at: https://doi.org/10.1002/ana.26137.
Oechtering, Johanna et al. (2021) ‘Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis’, Annals of Neurology, 90, pp. 477–489. Available at: https://doi.org/10.1002/ana.26137.
Allum, J.H.J. et al. (2021) ‘Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients’, Journal of the Neurological Sciences, 425. Available at: https://doi.org/10.1016/j.jns.2021.117432.
Allum, J.H.J. et al. (2021) ‘Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients’, Journal of the Neurological Sciences, 425. Available at: https://doi.org/10.1016/j.jns.2021.117432.
Tsagkas, Charidimos et al. (2021) ‘Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica’, Lancet, 397, p. 2194. Available at: https://doi.org/10.1016/S0140-6736(21)00986-7.
Tsagkas, Charidimos et al. (2021) ‘Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica’, Lancet, 397, p. 2194. Available at: https://doi.org/10.1016/S0140-6736(21)00986-7.
Lorscheider J et al. (2021) ‘Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis’, Journal of Neurology, 268(3), pp. 941–949. Available at: https://doi.org/10.1007/s00415-020-10226-6.
Lorscheider J et al. (2021) ‘Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis’, Journal of Neurology, 268(3), pp. 941–949. Available at: https://doi.org/10.1007/s00415-020-10226-6.
von Wyl V et al. (2021) ‘Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate’, Multiple Sclerosis Journal, 27(3), pp. 439–448. Available at: https://doi.org/10.1177/1352458520918489.
von Wyl V et al. (2021) ‘Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate’, Multiple Sclerosis Journal, 27(3), pp. 439–448. Available at: https://doi.org/10.1177/1352458520918489.
Todea, R. -A. et al. (2021) ‘Leman-PV as a clinical decision-support tool to assess MS activity: a multicentric longitudinal study at 1.5T and 3T MRI’, Multiple Sclerosis Journal. 12.10.2021, 27(2).
Todea, R. -A. et al. (2021) ‘Leman-PV as a clinical decision-support tool to assess MS activity: a multicentric longitudinal study at 1.5T and 3T MRI’, Multiple Sclerosis Journal. 12.10.2021, 27(2).
Sander, Laura et al. (2020) ‘Improving Accuracy of Brainstem MRI Volumetry: Effects of Age and Sex, and Normalization Strategies’, Frontiers in Neuroscience, 14. Available at: https://doi.org/10.3389/fnins.2020.609422.
Sander, Laura et al. (2020) ‘Improving Accuracy of Brainstem MRI Volumetry: Effects of Age and Sex, and Normalization Strategies’, Frontiers in Neuroscience, 14. Available at: https://doi.org/10.3389/fnins.2020.609422.
Jakimovski D et al. (2020) ‘Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study’, Multiple Sclerosis Journal, 26(13), pp. 1670–1681. Available at: https://doi.org/10.1177/1352458519881428.
Jakimovski D et al. (2020) ‘Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study’, Multiple Sclerosis Journal, 26(13), pp. 1670–1681. Available at: https://doi.org/10.1177/1352458519881428.
Kronlage, Cornelius et al. (2020) ‘Muscle stiffness, gait instability, and liver cirrhosis in Wilson’s disease’, The Lancet, 396(10256), p. 990. Available at: https://doi.org/10.1016/s0140-6736(20)31963-2.
Kronlage, Cornelius et al. (2020) ‘Muscle stiffness, gait instability, and liver cirrhosis in Wilson’s disease’, The Lancet, 396(10256), p. 990. Available at: https://doi.org/10.1016/s0140-6736(20)31963-2.
von Wyl V et al. (2020) ‘Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment’, European Journal of Neurology, 27(6), pp. 1066–1075. Available at: https://doi.org/10.1111/ene.14191.
von Wyl V et al. (2020) ‘Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment’, European Journal of Neurology, 27(6), pp. 1066–1075. Available at: https://doi.org/10.1111/ene.14191.
Benkert, P. et al. (2020) ‘Serum nfl z-scores derived from a large healthy control group reflect different levels of treatment effect in a real-world setting’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 194–195.
Benkert, P. et al. (2020) ‘Serum nfl z-scores derived from a large healthy control group reflect different levels of treatment effect in a real-world setting’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 194–195.
Cagol, A. et al. (2020) ‘Focal inflammatory activity and lesion repair are associated with brain atrophy rates in MS patients’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 395–395.
Cagol, A. et al. (2020) ‘Focal inflammatory activity and lesion repair are associated with brain atrophy rates in MS patients’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 395–395.
Oechtering, J. et al. (2020) ‘Intrathecal immunoglobulin m synthesis is associated with higher serum neurofilament light chain levels and increased mri disease activity in ms’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 165–165.
Oechtering, J. et al. (2020) ‘Intrathecal immunoglobulin m synthesis is associated with higher serum neurofilament light chain levels and increased mri disease activity in ms’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 165–165.
Sinnecker, Tim et al. (2020) ‘New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis’, Journal of Neurology. 14.10.2019, 267(1), pp. 192–202. Available at: https://doi.org/10.1007/s00415-019-09565-w.
Sinnecker, Tim et al. (2020) ‘New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis’, Journal of Neurology. 14.10.2019, 267(1), pp. 192–202. Available at: https://doi.org/10.1007/s00415-019-09565-w.
Sinnecker, T. et al. (2020) ‘Role of gadolinium-based contrast agents to detect subclinical disease activity in clinically stable patients in the swiss MS cohort study’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 422–423.
Sinnecker, T. et al. (2020) ‘Role of gadolinium-based contrast agents to detect subclinical disease activity in clinically stable patients in the swiss MS cohort study’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 422–423.
Yaldizli, O. et al. (2020) ‘Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 26–27.
Yaldizli, O. et al. (2020) ‘Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice’, Multiple Sclerosis Journal. 07.12.2020, 26(3, Supplement), pp. 26–27.
Kaufmann M et al. (2019) ‘A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis’, Frontiers in Neurology, 10, p. 953. Available at: https://doi.org/10.3389/fneur.2019.00953.
Kaufmann M et al. (2019) ‘A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis’, Frontiers in Neurology, 10, p. 953. Available at: https://doi.org/10.3389/fneur.2019.00953.
Ruberte, Esther et al. (2019) ‘Central slab versus whole brain to measure brain atrophy in multiple sclerosis’, European Neurology. 03.01.2019, 80(3-4), pp. 207–214. Available at: https://doi.org/10.1159/000495798.
Ruberte, Esther et al. (2019) ‘Central slab versus whole brain to measure brain atrophy in multiple sclerosis’, European Neurology. 03.01.2019, 80(3-4), pp. 207–214. Available at: https://doi.org/10.1159/000495798.
Findling O et al. (2018) ‘Balance changes in patients with relapsing-remitting multiple sclerosis: A pilot study comparing the dynamics of the relapse and remitting phases’, Frontiers in Neurology, 9(AUG), p. 686. Available at: https://doi.org/10.3389/fneur.2018.00686.
Findling O et al. (2018) ‘Balance changes in patients with relapsing-remitting multiple sclerosis: A pilot study comparing the dynamics of the relapse and remitting phases’, Frontiers in Neurology, 9(AUG), p. 686. Available at: https://doi.org/10.3389/fneur.2018.00686.
Barro C et al. (2018) ‘Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis’, Brain, 141(8), pp. 2382–2391. Available at: https://doi.org/10.1093/brain/awy154.
Barro C et al. (2018) ‘Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis’, Brain, 141(8), pp. 2382–2391. Available at: https://doi.org/10.1093/brain/awy154.
Lorscheider J et al. (2018) ‘Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis’, Multiple Sclerosis Journal, 24(6), pp. 777–785. Available at: https://doi.org/10.1177/1352458518768433.
Lorscheider J et al. (2018) ‘Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis’, Multiple Sclerosis Journal, 24(6), pp. 777–785. Available at: https://doi.org/10.1177/1352458518768433.
Miller DH et al. (2018) ‘Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study’, Annals of Clinical and Translational Neurology, 5(3), pp. 346–356. Available at: https://doi.org/10.1002/acn3.534.
Miller DH et al. (2018) ‘Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study’, Annals of Clinical and Translational Neurology, 5(3), pp. 346–356. Available at: https://doi.org/10.1002/acn3.534.
Neuhaus M et al. (2018) ‘Characterization of social cognition impairment in multiple sclerosis’, European Journal of Neurology. 24.10.2017, 25(1), pp. 90–96. Available at: https://doi.org/10.1111/ene.13457.
Neuhaus M et al. (2018) ‘Characterization of social cognition impairment in multiple sclerosis’, European Journal of Neurology. 24.10.2017, 25(1), pp. 90–96. Available at: https://doi.org/10.1111/ene.13457.
Yaldizli Ö et al. (2018) ‘Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis’, Multiple Sclerosis and Related Disorders. Elsevier B.V., 19. Available at: https://doi.org/10.1016/j.msard.2016.08.006.
Yaldizli Ö et al. (2018) ‘Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis’, Multiple Sclerosis and Related Disorders. Elsevier B.V., 19. Available at: https://doi.org/10.1016/j.msard.2016.08.006.
Barro, C. et al. (2017) ‘Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS’. SAGE PUBLICATIONS LTD, 23.
Barro, C. et al. (2017) ‘Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS’. SAGE PUBLICATIONS LTD, 23.
Lorscheider, J. et al. (2017) ‘Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set’. SAGE PUBLICATIONS LTD, 23. Available at: https://doi.org/10.26226/morressier.59a3edabd462b8028d895259.
Lorscheider, J. et al. (2017) ‘Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set’. SAGE PUBLICATIONS LTD, 23. Available at: https://doi.org/10.26226/morressier.59a3edabd462b8028d895259.
Sinnecker, T. et al. (2017) ‘Comparison between central and whole brain atrophy in multiple sclerosis measured by structural image evaluation using normalization of atrophy (SIENA)’. SAGE PUBLICATIONS LTD, 23.
Sinnecker, T. et al. (2017) ‘Comparison between central and whole brain atrophy in multiple sclerosis measured by structural image evaluation using normalization of atrophy (SIENA)’. SAGE PUBLICATIONS LTD, 23.
Disanto G et al. (2017) ‘Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis’, Annals of Neurology, 81(6), pp. 857–870. Available at: https://doi.org/10.1002/ana.24954.
Disanto G et al. (2017) ‘Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis’, Annals of Neurology, 81(6), pp. 857–870. Available at: https://doi.org/10.1002/ana.24954.
D’Souza M et al. (2017) ‘Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study’, Multiple Sclerosis, 23(4), pp. 597–603. Available at: https://doi.org/10.1177/1352458516657439.
D’Souza M et al. (2017) ‘Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study’, Multiple Sclerosis, 23(4), pp. 597–603. Available at: https://doi.org/10.1177/1352458516657439.
Kuhle J et al. (2017) ‘Serum neurofilament is associated with progression of brain atrophy and disability in early MS’, Neurology, 88(9), pp. 826–831. Available at: https://doi.org/10.1212/wnl.0000000000003653.
Kuhle J et al. (2017) ‘Serum neurofilament is associated with progression of brain atrophy and disability in early MS’, Neurology, 88(9), pp. 826–831. Available at: https://doi.org/10.1212/wnl.0000000000003653.
Hauser SL et al. (2017) ‘Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis’, New England Journal of Medicine. 21.12.2016, 376(3), pp. 221–234. Available at: https://doi.org/10.1056/nejmoa1601277.
Hauser SL et al. (2017) ‘Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis’, New England Journal of Medicine. 21.12.2016, 376(3), pp. 221–234. Available at: https://doi.org/10.1056/nejmoa1601277.
Montalban,Xavier et al. (2017) ‘Ocrelizumab versus placebo in primary progressive multiple sclerosis’, New England Journal of Medicine. 21.12.2016, 376(3), pp. 209–220. Available at: https://doi.org/10.1056/nejmoa1606468.
Montalban,Xavier et al. (2017) ‘Ocrelizumab versus placebo in primary progressive multiple sclerosis’, New England Journal of Medicine. 21.12.2016, 376(3), pp. 209–220. Available at: https://doi.org/10.1056/nejmoa1606468.
Pardini, M et al. (2016) ‘The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography’, European Journal of Neurology, 23(12), pp. 1769–1774. Available at: https://doi.org/10.1111/ene.13116.
Pardini, M et al. (2016) ‘The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography’, European Journal of Neurology, 23(12), pp. 1769–1774. Available at: https://doi.org/10.1111/ene.13116.
Pardini M et al. (2016) ‘Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry. 06.09.2016, 87(11), pp. 1212–1217. Available at: https://doi.org/10.1136/jnnp-2016-313979.
Pardini M et al. (2016) ‘Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry. 06.09.2016, 87(11), pp. 1212–1217. Available at: https://doi.org/10.1136/jnnp-2016-313979.
Barro, C. et al. (2016) ‘High sensitivity serum neurofilament-light chain measurements correlate with disease activity and disability in multiple sclerosis and are reduced after immunomodulatory treatment intervention.’ SAGE PUBLICATIONS LTD, 22.
Barro, C. et al. (2016) ‘High sensitivity serum neurofilament-light chain measurements correlate with disease activity and disability in multiple sclerosis and are reduced after immunomodulatory treatment intervention.’ SAGE PUBLICATIONS LTD, 22.
Callegari, Ilaria et al. (2016) ‘Agomelatine improves apathy in frontotemporal dementia’, Neurodegenerative Diseases. 27.05.2016, 16(5-6), pp. 352–356. Available at: https://doi.org/10.1159/000445873.
Callegari, Ilaria et al. (2016) ‘Agomelatine improves apathy in frontotemporal dementia’, Neurodegenerative Diseases. 27.05.2016, 16(5-6), pp. 352–356. Available at: https://doi.org/10.1159/000445873.
Lienert, C. et al. (2016) ‘Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.
Lienert, C. et al. (2016) ‘Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.
Ruberte, E. et al. (2016) ‘Lateral Ventricle Volume change is associated with neurological and cognitive disability in multiple sclerosis: a 5-years follow-up study using an automated lateral ventricle segmentation algorithm’. SAGE PUBLICATIONS LTD, 22.
Ruberte, E. et al. (2016) ‘Lateral Ventricle Volume change is associated with neurological and cognitive disability in multiple sclerosis: a 5-years follow-up study using an automated lateral ventricle segmentation algorithm’. SAGE PUBLICATIONS LTD, 22.
Ruberte, E. et al. (2016) ‘Validation of an automated lateral ventricle delineation algorithm (ALVIN) in multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.
Ruberte, E. et al. (2016) ‘Validation of an automated lateral ventricle delineation algorithm (ALVIN) in multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.
van de Pavert, S. H. et al. (2016) ‘Spatial and temporal characteristics of magnetisation transfer ratio changes in different corticothalamic systems in multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.
van de Pavert, S. H. et al. (2016) ‘Spatial and temporal characteristics of magnetisation transfer ratio changes in different corticothalamic systems in multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.
van der Logt RP et al. (2016) ‘The effect of vibrotactile biofeedback of trunk sway on balance control in multiple sclerosis’, Multiple Sclerosis and Related Disorders, 8, pp. 58–63. Available at: https://doi.org/10.1016/j.msard.2016.05.003.
van der Logt RP et al. (2016) ‘The effect of vibrotactile biofeedback of trunk sway on balance control in multiple sclerosis’, Multiple Sclerosis and Related Disorders, 8, pp. 58–63. Available at: https://doi.org/10.1016/j.msard.2016.05.003.
Yaldizli Ö et al. (2016) ‘HLA-DRB∗1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis’, Multiple Sclerosis and Related Disorders. 07.03.2016, 7, pp. 47–52. Available at: https://doi.org/10.1016/j.msard.2016.03.003.
Yaldizli Ö et al. (2016) ‘HLA-DRB∗1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis’, Multiple Sclerosis and Related Disorders. 07.03.2016, 7, pp. 47–52. Available at: https://doi.org/10.1016/j.msard.2016.03.003.
Datta, Gourab et al. (2016) ‘Cortical [11C]PBR28 PET Measures of Microglial Inflammation Explain Differences in Cognitive Performance of People with MS’, NEUROLOGY. WOS.ISTP, 86.
Datta, Gourab et al. (2016) ‘Cortical [11C]PBR28 PET Measures of Microglial Inflammation Explain Differences in Cognitive Performance of People with MS’, NEUROLOGY. WOS.ISTP, 86.
Yaldizli Ö et al. (2016) ‘The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis’, European Journal of Neurology, 23(3), pp. 510–519. Available at: https://doi.org/10.1111/ene.12891.
Yaldizli Ö et al. (2016) ‘The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis’, European Journal of Neurology, 23(3), pp. 510–519. Available at: https://doi.org/10.1111/ene.12891.
Disanto G et al. (2016) ‘Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome’, Journal of Neurology, Neurosurgery and Psychiatry. 25.02.2015, 87(2), pp. 126–129. Available at: https://doi.org/10.1136/jnnp-2014-309690.
Disanto G et al. (2016) ‘Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome’, Journal of Neurology, Neurosurgery and Psychiatry. 25.02.2015, 87(2), pp. 126–129. Available at: https://doi.org/10.1136/jnnp-2014-309690.
Yaldizli Ö et al. (2016) ‘Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study’, Multiple Sclerosis. 26.05.2015, 22(2), pp. 150–159. Available at: https://doi.org/10.1177/1352458515586085.
Yaldizli Ö et al. (2016) ‘Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study’, Multiple Sclerosis. 26.05.2015, 22(2), pp. 150–159. Available at: https://doi.org/10.1177/1352458515586085.
Disanto, G. et al. (2016) ‘The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options’, PLoS One, 11(3), p. e0152347. Available at: https://doi.org/10.1371/journal.pone.0152347.
Disanto, G. et al. (2016) ‘The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options’, PLoS One, 11(3), p. e0152347. Available at: https://doi.org/10.1371/journal.pone.0152347.
Kuhle, Jens et al. (2016) ‘Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity’, Multiple Sclerosis Journal, 22(12), pp. 1550–1559. Available at: https://doi.org/10.1177/1352458515623365.
Kuhle, Jens et al. (2016) ‘Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity’, Multiple Sclerosis Journal, 22(12), pp. 1550–1559. Available at: https://doi.org/10.1177/1352458515623365.
Pardini M et al. (2016) ‘Prevalence and cognitive underpinnings of isolated apathy in young healthy subjects’, Journal of Affective Disorders. 08.10.2015, 189, pp. 272–275. Available at: https://doi.org/10.1016/j.jad.2015.09.062.
Pardini M et al. (2016) ‘Prevalence and cognitive underpinnings of isolated apathy in young healthy subjects’, Journal of Affective Disorders. 08.10.2015, 189, pp. 272–275. Available at: https://doi.org/10.1016/j.jad.2015.09.062.
Pardini M et al. (2015) ‘Motor network efficiency and disability in multiple sclerosis’, Neurology. 28.08.2015, 85(13), pp. 1115–1122. Available at: https://doi.org/10.1212/wnl.0000000000001970.
Pardini M et al. (2015) ‘Motor network efficiency and disability in multiple sclerosis’, Neurology. 28.08.2015, 85(13), pp. 1115–1122. Available at: https://doi.org/10.1212/wnl.0000000000001970.
Liu Z et al. (2015) ‘Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis’, Brain. 29.03.2015, 138(5), pp. 1239–1246. Available at: https://doi.org/10.1093/brain/awv065.
Liu Z et al. (2015) ‘Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis’, Brain. 29.03.2015, 138(5), pp. 1239–1246. Available at: https://doi.org/10.1093/brain/awv065.
Kuhle, J. et al. (2015) ‘Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study’, Multiple Sclerosis Journal, 21(8), pp. 24–1013. Available at: https://doi.org/10.1177/1352458514568827.
Kuhle, J. et al. (2015) ‘Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study’, Multiple Sclerosis Journal, 21(8), pp. 24–1013. Available at: https://doi.org/10.1177/1352458514568827.
Liu Z et al. (2015) ‘Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis’, Multiple Sclerosis and Related Disorders. 18.11.2014, 4(1), pp. 52–57. Available at: https://doi.org/10.1016/j.msard.2014.11.004.
Liu Z et al. (2015) ‘Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis’, Multiple Sclerosis and Related Disorders. 18.11.2014, 4(1), pp. 52–57. Available at: https://doi.org/10.1016/j.msard.2014.11.004.
Chard,DT et al. (2015) ‘Association of Multiple Sclerosis Normal Appearing White Matter Abnormality with Periventricular Location and Secondary Progression’, p. P6.126.
Chard,DT et al. (2015) ‘Association of Multiple Sclerosis Normal Appearing White Matter Abnormality with Periventricular Location and Secondary Progression’, p. P6.126.
Pardini,M et al. (2015) ‘The relationship of a multi-parameter MRI measure of motor network efficiency with disability in multiple sclerosis’, p. P6.129.
Pardini,M et al. (2015) ‘The relationship of a multi-parameter MRI measure of motor network efficiency with disability in multiple sclerosis’, p. P6.129.
Yaldizli,O et al. (2015) ‘Diffusion Tensor Imaging Abnormalities in Multiple Sclerosis Cortical Lesions and Normal-Appearing Grey Matter and their Associations with Disability’, p. P6.108.
Yaldizli,O et al. (2015) ‘Diffusion Tensor Imaging Abnormalities in Multiple Sclerosis Cortical Lesions and Normal-Appearing Grey Matter and their Associations with Disability’, p. P6.108.